The BALANCE trial

The Lancet

Volumn 375, Issue 9723, 2010, Pages 1343-1344

  Fountoulakis, Konstantinos N ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

LITHIUM; VALPROIC ACID; LITHIUM CARBONATE; TRANQUILIZER;

BIPOLAR I DISORDER; CLINICAL PRACTICE; CLINICAL PROTOCOL; CLINICAL RESEARCH; DRUG POTENTIATION; DRUG WITHDRAWAL; HUMAN; LETTER; MONOTHERAPY; MOOD DISORDER; PRIORITY JOURNAL; RELAPSE; STATISTICAL SIGNIFICANCE; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; BIPOLAR DISORDER; DRUG COMBINATION; NOTE;

ANTIMANIC AGENTS; BIPOLAR DISORDER; DRUG THERAPY, COMBINATION; HUMANS; LITHIUM CARBONATE; VALPROIC ACID;

EID: 77950831381     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(10)60569-7     Document Type: Letter

References (5)

1. The BALANCE investigators and collaborators. Lithium plus valproate combination therapy versus monotherapy for relapse prevention in bipolar I disorder (BALANCE): a randomised open-label trial. Lancet 375 (2010) 385-395
2. Bowden C.L., Brugger A.M., Swann A.C., et al., for the Depakote Mania Study Group. Efficacy of divalproex vs lithium and placebo in the treatment of mania. JAMA 271 (1994) 918-924
3. Post R., Leverich G., Altshuler L., and Mikalauskas K. Lithium-discontinuation-induced refractoriness: preliminary observations. Am J Psychiatry 149 (1992) 1727
4. Bauer M. Refractoriness induced by lithium discontinuation despite adequate serum lithium levels. Am J Psychiatry 151 (1994) 1522
5. Kleindienst N., and Greil W. Lithium in the long-term treatment of bipolar disorders. Eur Arch Psychiatry Clin Neurosci 253 (2003) 120-125